<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66777">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02236520</url>
  </required_header>
  <id_info>
    <org_study_id>141382</org_study_id>
    <nct_id>NCT02236520</nct_id>
  </id_info>
  <brief_title>Tissue Sodium in Pre-hypertensive Patients</brief_title>
  <official_title>Tissue Sodium in Pre-hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease is the first common cause of death worldwide. Hypertension is the
      number one driving risk factor. Hypertension has long been associated with dietary salt
      intake. We believe that the accumulation of salt in the interstitium and inside cells
      represents a neglected risk factor, which initiates a pro-inflammatory state, chronically
      increases blood pressure, and leads to systemic energy imbalance. We will explore the
      concept that Na+ storage in the skin and in muscle is associated with increased blood
      pressure, a pro-inflammatory state, and reduced insulin sensitivity. We will do so by
      addressing the following specific aims:

        -  Specific Aim 1: To test the hypothesis that African Americans are characterized by
           increased tissue Na+ storage, which is paralleled by higher blood pressure, reduced
           forearm blood flow, and enhanced pulse wave velocity

        -  Specific Aim 2: To test the hypothesis that treatment with spironolactone reduces
           tissue Na+ content

        -  Specific Aim 3: To test the hypothesis that Na+ storage leads to immune cell activation

        -  Specific Aim 4: To test the hypothesis that the accumulation of salt in skin and muscle
           is associated with decreased insulin sensitivity and propensity to diabetes mellitus
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in Na+ tissue stores by study arm</measure>
    <time_frame>baseline and 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg capsule administered orally 1 per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg capsule administered orally 1 per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diet of 6 g salt per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule administered orally 1 per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <arm_group_label>Chlorthalidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet</intervention_name>
    <arm_group_label>Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30 to 80 years old;

          -  Systolic blood pressures between 120 to 139 mmHg and/or diastolic blood pressure
             between 80-89 mmHg;

          -  Ability to give informed consent.

        Exclusion Criteria:

          -  Pregnancy;

          -  Intolerance to study protocols;

          -  Acute cardiovascular events within the previous 6 months;

          -  Impaired renal function [estimated glomerular filtration rate (GFR) &lt; 45
             ml/min/1.73m^2];

          -  Current or recent treatment with systemic glucocorticoid therapy (within 1 month of
             enrollment);

          -  Current use of anti-hypertensive medication;

          -  Diabetes mellitus requiring medical therapy;

          -  Morbid obesity (BMI &gt; 45);

          -  Prior adverse reaction to a thiazide or spironolactone;

          -  Claustrophobia preventing the patient from having an MRI or other contraindications
             to MRI;

          -  Impaired hepatic function (aspartate amino transaminase and/or alanine amino
             transaminase &gt; 1.5x upper limit of normal range);

          -  Current illicit drug use;

          -  Sexually active women of childbearing potential** who are unwilling to practice
             adequate contraception during the study [adequate contraceptive measures include
             stable use of oral contraceptives or other prescription pharmaceutical contraceptives
             for 2 or more menstrual cycles prior to screening; intrauterine device (IUD);
             bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or
             jelly, or diaphragm plus contraceptive sponge, foam, or jelly].

               -  Postmenopausal women must be amenorrheic for at least 12 months in order not to
                  be considered of child bearing potential. Pregnancy testing and contraception
                  are not required for women with documented hysterectomy or tubal ligation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alp Ikizler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Titze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alp Ikizler, MD</last_name>
    <phone>615-343-6104</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muge Deger, MD</last_name>
      <phone>615-343-6225</phone>
      <email>serpil.deger@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Alp Ikizler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>September 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alp Ikizler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Na+ MRI</keyword>
  <keyword>salt stores</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
